London, England -- (SBWIRE) -- 03/30/2012 -- The global Chronic Heart Failure (CHF) therapeutics market, valued at $3,171.3m in 2006, grew at a Compound Annual Growth Rate (CAGR) of 4.0% to $3,849.9m in 2011. GlobalData’s analysis suggests that the global CHF therapeutics market will grow at a CAGR of 3.1% during the forecast period to $4,918.4m by 2019. This growth will be primarily due to the expected launch of LCZ696 in 2015. The treatment-seeking population is expected to grow due to increased life expectancy and awareness of health among patients, as well as growth in the aging population more susceptible to Acute Heart Failure (AHF). Competition in the CHF therapeutics market is weak, as it is dominated by generic drugs such as beta-blockers (metropolol), diuretics (furosemide, spironolactone), digoxin, carvedilol and ramipril. Diovan (valsartan) is the only branded product, but it is expected to lose its patent protection in 2012 in the US.

GlobalData’s analysis shows that the current CHF therapeutics market is dominated by generics, which do not treat the underlying cause of the disease. Digoxin, ramipril, carvedilol, metoprolol and Diovan are examples of drugs used to manage the symptoms of CHF, but none have disease-modifying mechanisms.

GlobalData’s analysis shows that there are 41 molecules under development for the treatment of CHF. Of these, 78% are First-in-Class (FIC).

There are 10 molecules in Phase III, comprising 25% of the CHF therapeutics pipeline. Of these, 80% are FIC and are being developed for the treatment and management of CHF. LCZ696, a FIC molecule in Phase III, is intended to improve cardiac function in CHF patients. Additionally, lixivaptan, Aranesp (darbepoetin alfa), recombinant human neuregulin-1, Tekturna (aliskiren), and its Fixed Dose Combinations (FDCs) are being investigated to manage early stage CHF patients.

For Sample Pages, please click or add the below link to your browser:
http://www.globalmarketsdirect.com/SamplePdfRequest.aspx?ID=Chronic-Heart-Failure-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2018&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report&companyID=sbwire

There are 18 molecules in Phase II, accounting for 45% of the CHF therapeutics pipeline. The majority are being clinically tested for safety and efficacy in improving cardiac function. Phase I of the CHF pipeline accounts for only five molecules, or 12% of the pipeline. The Preclinical Phase contains five molecules, or 12%, and the Discovery Phase comprises three molecules, or 5% of the pipeline.

The pipeline assessment suggests that the CHF therapeutics pipeline is strong, with 30 FIC molecules under development, some of which stand a good chance of becoming the standard first-in-line therapy for the treatment and management of CHF.

Stem cell therapy is capable of significantly improving the CHF treatment pattern. The stem cell therapies in the pipeline will restore cardiac muscle function by regenerating and strengthening the heart muscle cells, potentially improving quality of life for CHF patients

Industry analysis specialist, GlobalData, has released its new report, “Chronic Heart Failure (CHF) Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information on the global CHF therapeutics market, and analyzes a number of key areas. It identifies the key trends shaping and driving the global CHF therapeutics market and provides insights into the current competitive landscape and emerging companies. Most importantly, the report provides valuable insights into the pipeline products within the global CHF sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts

For further details, please click or add the below link to your browser:
http://www.globalmarketsdirect.com/Report.aspx?ID=Chronic-Heart-Failure-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2018&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare&companyID=sbwire

Visit our report store: http://www.globalmarketsdirect.com

For more details contact:
pressreleases@globalmarketsdirect.com
North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782